1. health and fitness

Mitogen Activated Protein Kinase 3 Market Size, Definition,
Treatment, Symptoms, Pipeline Review, H1 2016
Summary
Global Markets Direct's, 'Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or
Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Pipeline Review, H1 2016', provides in depth
analysis on Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular
Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted pipeline therapeutics.
The report provides comprehensive information on the Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or
Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24), targeted
therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of
administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest news and press releases. Additionally, the
report provides an overview of key players involved in Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or
Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted
therapeutics development and features dormant and discontinued projects.
View Summary of This Report @ http://www.radiantinsights.com/research/mitogen-activated-protein-kinase-3
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and
nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 3 (MAP
Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24)
- The report reviews Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or
Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics under development by
companies and universities/research institutes based on information derived from company and industry-specific
sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till
discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description,
descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or InsulinStimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics
and enlists all their major and minor projects
- The report assesses Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or
Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics based on mechanism of
action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or InsulinStimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics
Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/mitogen-activated-proteinkinase-3/request-sample
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal
Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) Overview 6
Therapeutics Development 7
Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal
Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Products under Development by Stage of Development 7
Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal
Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Products under Development by Therapy Area 8
Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal
Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Products under Development by Indication 9
Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal
Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal
Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Products under Development by Companies 12
Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal
Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal
Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) - Companies Involved in Therapeutics Development 20
AGV Discovery, SAS 20
View Summary of This Report @ http://www.radiantinsights.com/research/mitogen-activated-protein-kinase-3
About Us:
Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence
requirements. We assist and facilitate organizations and individuals procure market research reports, helping them
in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries
and a host of micro markets. In addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research
solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street,
Suite 3036 San Francisco,
CA 94105 United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Website: http://www.radiantinsights.com/
Email: [email protected]
Visit our Blog: http://chemicalsandmaterialsri.blogspot.com